Adenovirus replication-competent vectors (KD1, KD3) complement the cytotoxicity and transgene expression from replication-defective vectors (Ad-GFP, Ad-Luc)

Cancer Gene Therapy

Volumn 9, Issue 8, 2002, Pages 651-654

  Habib, Nagy A ^a   Mitry, Ragai ^a   Seth, Prem ^b   Kuppuswamy, Mohan ^c   Doronin, Konstantin ^c   Toth, Karoly ^c   Krajcsi, Peter ^c   Tollefson, Ann E ^c   Wold, William S M ^c  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b Human Research Institute   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ad E1B deleted; Ad p53; Adenovirus; Cancer; dl1520; Gene therapy; KD1; KD3; p53

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; LUCIFERASE; PHOTOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; GENE EXPRESSION; LUNG TUMOR; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TRANSGENE; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; ADENOVIRUS; ANIMAL; CELL CULTURE; CELL SURVIVAL; DEFECTIVE VIRUS; GENE VECTOR; GENETICS; HUMAN; PHYSIOLOGY;

ADENOVIRIDAE; ANIMAL; CELL SURVIVAL; DEFECTIVE VIRUSES; GENETIC VECTORS; HUMAN; LUCIFERASE; LUMINESCENT PROTEINS; MICE; MICE, NUDE; SUPPORT, U.S. GOV'T, P.H.S.; TRANSGENES; TUMOR CELLS, CULTURED; VIRUS REPLICATION; ANIMALS; GREEN FLUORESCENT PROTEINS; HUMANS; LUCIFERASES;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; MUS MUSCULUS;

EID: 0036021893     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700481     Document Type: Article

References (31)

1. Adenoviruses
2. In vivo and ex vivo gene therapy strategies to treat tumors using adenovirus gene transfer vectors
3. Replicative adenoviruses for cancer therapy
4. DNA virus replication
5. Regulation of apoptosis by adenovirus E1A and E1B oncogenes
6. Immune responses to adenoviruses: Viral evasion mechanisms and their implications for the clinic
7. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
8. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
9. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
10. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
11. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins
12. Adenovirus E1B-58 kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells
13. Adenovirus EIB 55K represses p53 activation in vitro
14. Corepressor required for adenovirus E1B 55, 000-molecular-weight protein repression of basal transcription
15. Inactivation of p53 but not p73 by adenovirus type 5 E1B 55-kilodalton and E4 34-kilodalton oncoproteins
16. Distinct regulation of p53 and p73 activity by adenovirus E1A, E1B, and E4orf6 proteins
17. E1B 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53
18. E4 gene function in adenovirus, adenovirus vector and adeno-associated virus infections
19. p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication
20. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: The importance of the adenoviral E1B-55 kD gene
21. The replicative capacities of large EIB-null group A and group C adenoviruses are independent of host cell p53 status
22. Tumor-specific, replication-competent adenovirus vectors overexpressing the Adenovirus Death Protein
23. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
24. The addition of adenovirus type 5 region E3 enables Calydon virus 787 to eliminate distant prostate tumor xenografts
25. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of Calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy
26. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma
27. Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis
28. The E3-11.6 kDa Adenovirus Death Protein (ADP) is required for efficient cell death: Characterization of cells infected with adp mutants
29. The adenovirus death protein (E3-11.6 K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells
30. Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus
31. Adenovirus-mediated transfer of p53 and Fas ligand drastically enhances apoptosis in gliomas